Cargando…

Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone

BACKGROUND: The purpose of this study was investigate the dose proportionality of a novel, once-daily, controlled-release formulation of hydromorphone that utilizes the OROS(® )Push-Pull™ osmotic pump technology. METHODS: In an open-label, four-way, crossover study, 32 healthy volunteers were random...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sathyan, Gayatri, Xu, Emily, Thipphawong, John, Gupta, Suneel K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808051/ https://www.ncbi.nlm.nih.gov/pubmed/17270058 http://dx.doi.org/10.1186/1472-6904-7-3

Ejemplares similares

Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007)

A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
por: Wallace, M, et al.
Publicado: (2007)

A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009)

Single dose epidural hydromorphone in labour pain: maternal pharmacokinetics and neonatal exposure
por: Puhto, Terhi, et al.
Publicado: (2020)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(® )hydromorphone in patients with chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2009)

Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
por: Kim, Yo Han, et al.
Publicado: (2015)

Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2016)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

Controlled-release hydromorphone and risk of infection in adults: a systematic review
por: Tricco, Andrea C., et al.
Publicado: (2023)

USL255 extended-release topiramate: Dose-proportional pharmacokinetics and tolerability in healthy volunteers
por: Clark, Annie M, et al.
Publicado: (2014)

Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain
por: Nakatani, Toshihiko, et al.
Publicado: (2023)

Selection of 12‐Hour Sustained‐Release Acetaminophen (Paracetamol) Formulation Through Comparison of Pharmacokinetic Profiles of 4 Sustained‐Release Prototype Formulations and Standard Acetaminophen Formulation: An Open‐Label, Randomized, Proof‐of‐Principle Pharmacokinetic Study
por: Yue, Yong, et al.
Publicado: (2017)

Movement in High School: Proportion of Chinese Adolescents Meeting 24-Hour Movement Guidelines
por: Ying, Li, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs
por: Klotsman, Michael, et al.
Publicado: (2021)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

Acute suicidal ideations responsive to hydromorphone
por: Rotchford, James Kimber
Publicado: (2019)

Unintentional administration of intra‐articular hydromorphone
por: Doyle, Stephen, et al.
Publicado: (2021)

Analgosedation: The Use of Fentanyl Compared to Hydromorphone
por: Choi, Hahnl, et al.
Publicado: (2021)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Proportion of Chinese Children and Adolescents Meeting 24-Hour Movement Guidelines and Associations with Overweight and Obesity
por: Sun, Yi, et al.
Publicado: (2023)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Mycobacteremia from Crushed Hydromorphone Tablet Injection
por: Banno, Joseph M, et al.
Publicado: (2017)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults
por: Liu, Tao, et al.
Publicado: (2019)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

The protective effect of hydromorphone to ischemia in rat glial cells
por: Kim, Young Sung, et al.
Publicado: (2016)

Two orthorhombic polymorphs of hydromorphone
por: Mazurek, Jaroslaw, et al.
Publicado: (2016)

Hydromorphone/lorazepam/morphine overdose: Coma: case report
Publicado: (2019)

Proportion of children meeting recommendations for 24-hour movement guidelines and associations with adiposity in a 12-country study
por: Roman-Viñas, Blanca, et al.
Publicado: (2016)

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers
por: Labonté, Laura E., et al.
Publicado: (2021)

Preliminary Investigation into a Novel Sustained-Release Formulation of Meloxicam in Sheep (Ovis aries)—Pharmacokinetic Profile
por: Plummer, Christine, et al.
Publicado: (2021)

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)
por: Inoue, Satoshi, et al.
Publicado: (2017)

Evaluation of a 12‐Hour Sustained‐Release Acetaminophen (Paracetamol) Formulation: A Randomized, 3‐Way Crossover Pharmacokinetic and Safety Study in Healthy Volunteers
por: Yue, Yong, et al.
Publicado: (2017)

Patient-controlled analgesia in the pediatric population: morphine versus hydromorphone
por: DiGiusto, Matthew, et al.
Publicado: (2014)

Recrudescence of Focal Stroke Symptoms during Pain Management with Hydromorphone
por: Bernstock, Joshua D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_trq95hsujq3jieu4gmpla9p35o